Core Viewpoint - The company plans to sell 100% of its subsidiary Complete Genomics, Inc. for approximately $50 million, while also upgrading sequencing technology licensing in North America, marking a strategic shift towards technology output and improved financial performance [2][3]. Financial Aspects - The transaction will generate multiple financial benefits, including $50 million from the equity sale, a $20 million upfront payment for technology licensing due by November 2025, and an additional $20 million milestone payment, enhancing cash flow and current profits [3]. - The divestiture of the North American business unit is expected to reduce annual operating losses by $40 million to $50 million, thereby improving overall profitability [3]. - The licensing fee rate for the StandardMPS technology is set at 8.71%, with a tiered revenue-sharing model based on global net sales of the partner's products, creating a stable long-term cash flow [3]. Business and Strategic Aspects - The transaction optimizes global layout and upgrades the business model, allowing the company to leverage local partners' resources and compliance capabilities for North American market operations [3]. - The deal transforms high-volatility direct market operations into structured licensing income, reducing operational uncertainty and enhancing compliance [3]. - The reverse licensing and intellectual property isolation mechanisms strengthen the company's technological security [3]. Industry Perspective - Analysts suggest that this transaction redefines the company's valuation logic, moving beyond the perception of being merely a device manufacturer to a model akin to leading firms in innovative pharmaceuticals [4]. - The transaction optimizes the allocation of non-core mature technologies and loss-making assets, improving asset return rates and demonstrating the international competitiveness of domestic high-tech enterprises [4]. - This move serves as a benchmark for Chinese scientific instrument technology going global, providing a valuable case for value realization in the industry and opening up significant valuation potential [4].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.869 billion yuan for the first three quarters of 2025, showing a year-over-year decrease of 0.01%, while the net profit attributable to the parent company was -120 million yuan, an increase of 74.20% year-over-year [4][5] - In Q3 2025, the company achieved a revenue of 755 million yuan, representing a year-over-year growth of 14.45%, and a net profit of -16 million yuan, up 90.31% year-over-year [5] - The revenue growth in Q3 2025 is attributed to the shift of domestic customers' data platforms and increased installation and usage of related reagents due to Illumina being listed as an unreliable entity by the Ministry of Commerce [5][6] Financial Performance - The company’s revenue for Q1, Q2, and Q3 of 2025 was 455 million yuan (down 14.26% year-over-year), 659 million yuan (down 2.93% year-over-year), and 755 million yuan (up 14.45% year-over-year) respectively [5] - The company’s expense ratios for sales, management, and R&D in Q3 2025 were 23.19%, 11.19%, and 14.80%, respectively, showing significant reductions both year-over-year and quarter-over-quarter [5] - The company has entered a new phase of globalization by licensing its sequencing technology to Swiss Rockets, with an initial payment of 20 million USD and milestone payments totaling at least 120 million USD [6] Revenue and Profit Forecast - The company is expected to achieve revenues of 2.824 billion yuan, 3.341 billion yuan, and 3.943 billion yuan for the years 2025, 2026, and 2027, with year-over-year growth rates of -6.3%, 18.3%, and 18.0% respectively [7] - The net profit attributable to the parent company is projected to be -98 million yuan, 160 million yuan, and 382 million yuan for the years 2025, 2026, and 2027, with year-over-year growth rates of 83.6%, 262.9%, and 138.6% respectively [7][10]